Asian Paints

2764.8 -14.60

Cipla

1517.4 5.10

Eicher Motors

7229 -27.00

Nestle India

1238.3 23.30

Grasim Inds

2836.7 38.90

Hindalco Inds.

852.1 27.75

Hind. Unilever

2260.6 -45.00

ITC

400.1 -2.80

Trent

4075.4 27.90

Larsen & Toubro

4074.1 70.20

M & M

3679.6 14.40

Reliance Industr

1556.5 11.50

Tata Consumer

1149.3 7.20

Tata Motors PVeh

347.45 0.80

Tata Steel

171.89 5.51

Wipro

260.6 1.35

Apollo Hospitals

7101 91.50

Dr Reddy's Labs

1279.3 5.80

Titan Company

3880.2 35.40

SBI

963.15 -0.10

Shriram Finance

848 0.85

Bharat Electron

389.45 1.95

Kotak Mah. Bank

2176.6 -3.60

Infosys

1598.2 0.20

Bajaj Finance

1017.3 10.90

Adani Enterp.

2282.4 4.70

Sun Pharma.Inds.

1793.5 -13.70

JSW Steel

1125.5 20.10

HDFC Bank

1001.5 1.20

TCS

3220.5 28.60

ICICI Bank

1366 6.00

Power Grid Corpn

263.6 -1.20

Maruti Suzuki

16522 274.00

Axis Bank

1286.1 13.40

HCL Technologies

1673.2 0.80

O N G C

238.02 -0.39

NTPC

325.05 2.45

Coal India

383.35 -0.65

Bharti Airtel

2083.4 30.20

Tech Mahindra

1578.4 10.20

Jio Financial

300.75 2.30

Adani Ports

1522.8 18.80

HDFC Life Insur.

777.5 2.30

SBI Life Insuran

2025.9 19.00

Max Healthcare

1081.3 -6.60

UltraTech Cem.

11723 251.00

Bajaj Auto

9015 -38.50

Bajaj Finserv

2083.1 17.30

Interglobe Aviat

4860.5 41.50

Eternal Ltd

298.05 7.10

IPO-Synopsis
Park Medi World Ltd
Initial public offer of up to [*] equity shares of face value of Rs. 2/- each ("Equity Shares") of Park Medi World Limited ("Company") for cash at a price of Rs. [*] per equity share (including a share premium of Rs. [*] per equity share) ("Offer Price") aggregating up to Rs. 920.00 crores comprising a fresh issue of up to [*] equity shares of face value of Rs. 2/- each aggregating up to Rs. 770.00 crores by the company ("Fresh Issue") and an offer for sale of up to [*] equity shares of face value of Rs. 2/- each aggregating up to Rs. 150.00 crores ("Offered Shares") by Ajit Gupta ("the Promoter Selling Shareholder") ("Offer for Sale", and together with the fresh issue, the "Offer"). The company, in consultation with the brlms, may consider an issue of specified securities, as may be permitted under applicable law, aggregating up to Rs. 192.00 crores prior to filing of the ("pre-ipo placement"). The pre-ipo placement, if undertaken, will be at a price to be decided by the company, in consultation with the brlms. if the pre-ipo placement is completed, the amount raised pursuant to the pre-ipo placement will be reduced from the fresh issue, subject to compliance with Rule 19(2)(b) of the securities contracts (Regulation) Rules, 1957, as amended. The pre-ipo placement, if undertaken, shall not exceed 20 % of the size of the fresh issue. Prior to the completion of the offer, the company shall appropriately intimate the subscribers to the pre-ipo placement, prior to allotment pursuant to the pre-ipo placement, that there is no guarantee that the company may proceed with the offer or the offer may be successful and will result into listing of the equity shares on the stock exchanges. Further, relevant disclosures in relation to such intimation to the subscribers to the pre-ipo placement (if Undertaken). The face value of equity shares is Rs. 2/- each. The offer price is [*] times the face value of the equity shares. Price Band: Rs. 154 to Rs. 162 per equity share of face value of Rs. 2 each. The floor price is 77 times of the face value and the cap price is 81 times of the face value of the equity shares. Bids can be made for a minimum of 92 equity shares and in multiples of 92 equity shares thereafter.
Issue
Opens On Closes On
10-Dec-25 12-Dec-25
Money Payable On
Application Allotment
154.00 0.00
Minimum Application for shares in Nos : 92 Further Multiples of : 92
Cr Lead Managers to the Issue
Project Cost (.Cr) 0.00 CLSA India Pvt ltd
Project Financed through Current Offer (.Cr) 920.00  
Post Issue Equity Share Capital (.Cr) 86.39
Issue Price () 154.00
Projects
Repayment/Prepayment in full or in part of certain outstanding borrowings availed by the company and certain of the company subsidiaries
Funding capital expenditure for development of new hospital by its Subsidiary Park Medicity (NCR)
Funding capital expenditure for purchase of medical equipment by the Company and its Subsidiaries, Blue Heavens and Ratangiri
General corporate purposes
Promoted By
Ajit Gupta
Ankit Gupta
Nidhi Gupta
Listing At
BSE
NSE
Registrar to the Issue
No Data Available

DJIA 48727.83
649.07 1.35%
S&P 500 6922.99
15.31 0.22%
HANG SENG 25976.80
446.28 1.75%
NIKKEI 225 50843.93
695.11 1.39%
FTSE 100 9710.82
55.29 0.57%
NIFTY 26046.95
148.40 0.57%
×
Ask Your Question
close
refresh